越狱

望花区：做大做强民营经济 高质量发展活力澎湃_我的网站

一 |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    民营经济是社会主义市场经济的重要组成部分，是推动区域经济增长的重要突破口。

二 | 为做大做强民营经济，支持企业抢抓新时代东北全面振兴新机遇，放开手脚、加速发展，年初以来，望花区坚持“项目为王”，坚定不移大抓项目、抓大项目，为打好打赢全面振兴新突破三年行动攻坚之年攻坚之战蓄力聚能。         　　今年年初，辽宁鸿邦装备技术有限公司接到了一笔额度为70万元的订单，为太原锅炉电力工程有限公司“量身”定制滤袋。为满足客户需求，确保按时交货，企业制定了详细的生产计划，保质保量完成订单任务。         　　辽宁鸿邦装备制造有限公司是望花区重点培育的装备制造企业，自2018年投产运营以来，已发展成为国内唯一一家从事玻璃纤维及纱线制造、基布纺织、滤袋及袋笼加工的全产业链式生产企业，是国内环保产业的骨干企业之一。公司坚持智能化生产和数字化经营管理，以“智”赋“质”提升产量质量，在国际、国内均有较强市场竞争力。

三 |          　　抚顺晟业环保科技有限公司炉渣综合利用项目是望花经济开发区近年来延伸产业链条开展招商实现落地的项目之一，通过对炉渣的分选处理和深加工，实现炉渣资源的无害化处理和二次利用，对改善生态环境起到积极作用。

四 | 项目总投资3500万元，总用地面积25.1亩，现有员工28人。该项目于2023年4月开工建设，8月成功试车生产。项目建成投产后，平均年处理炉渣20万吨，年产值2000万元，年利税200万元左右，将有效解决我市城市生活垃圾处理难题，实现生活垃圾无害化、减量化、资源化利用。         　　走进抚顺新钢铁有限责任公司炼钢厂，新建的5.7万平方米的厂房内，两座120吨转炉正在运转，这里就是抚顺新钢铁数字化、智能化、绿色化转型升级典范——转炉节能环保升级改造项目。

五 | 新棒材作业区，全自动机械臂目前已经上线，公司轧钢厂实现全连轧、棒材和新棒材3个作业区、5个收集区的生产过程自动化。这是抚顺新钢铁降低员工劳动强度、提高岗位操作安全性，推动生产过程自动化和智能化的又一成功实践。         　　进入四季度，望花区持续推进“千人进千企”暨“项目管家”工作，紧盯关键环节和重点任务，靶向解决难点、堵点问题，进一步发挥“项目管家”在服务项目建设及企业发展中的作用，为攻坚之年攻坚之战蓄力赋能，全力确保2024年目标任务圆满完成。                    责任编辑：李丹。

Current article:http://www.chenzhuaigecoupuhongyuntuizei.sbs/kt2o1/8d179o.html

Published on:10:08:56